ProMIS Neurosciences Inc. 8K

ProMIS Neurosciences Inc. announced Q2 2026 results featuring positive blinded interim Phase 1b PMN310 data in early Alzheimer’s disease and a materially strengthened cash runway expected to fund operations through 2027.

On August 13, 2026, ProMIS Neurosciences Inc. reported its second quarter 2026 financial results and corporate updates, highlighting positive blinded six‑month interim safety and biomarker data from its Phase 1b PRECISE-AD trial of PMN310 in early Alzheimer’s disease, including zero cases of ARIA-E across all 136 safety-evaluable participants and genotypes and modest declines in plasma pTau217 and CSF MTBR-tau243, while confirming that all patients are expected to complete 12 months of dosing by Q4 2026 with unblinded topline data anticipated in Q1 2027; the company also reported a strengthened cash position of $53.4 million as of June 30, 2026, driven by a $70.1 million January 2026 private placement, providing runway through 2027 and supporting continued development of PMN310 and earlier-stage programs PMN267 and PMN442.

Filing Facts

CIK

1374339

Ticker

-

Form

8K

Source Type

sec

Accession

0001104659-26-095905

Alert Tier

7